DAKLINZA is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by E.r. Squibb & Sons, L.l.c.. The primary component is Daclatasvir Dihydrochloride.
Product ID | 0003-0215_780ae42b-9b05-4a02-9529-5e45dbb460f6 |
NDC | 0003-0215 |
Product Type | Human Prescription Drug |
Proprietary Name | DAKLINZA |
Generic Name | Daclatasvir |
Dosage Form | Tablet |
Route of Administration | ORAL |
Marketing Start Date | 2015-07-27 |
Marketing End Date | 2019-12-31 |
Marketing Category | NDA / NDA |
Application Number | NDA206843 |
Labeler Name | E.R. Squibb & Sons, L.L.C. |
Substance Name | DACLATASVIR DIHYDROCHLORIDE |
Active Ingredient Strength | 60 mg/1 |
Pharm Classes | Hepatitis C Virus NS5A Inhibitor [EPC],P-Glycoprotein Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA] |
NDC Exclude Flag | N |
Marketing Start Date | 2015-07-27 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA206843 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2015-07-27 |
Marketing End Date | 2019-12-31 |
Ingredient | Strength |
---|---|
DACLATASVIR DIHYDROCHLORIDE | 60 mg/1 |
SPL SET ID: | 9803a6ff-8a3e-4c64-b3d0-7825c7123bf2 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
0003-0011 | DAKLINZA | daclatasvir |
0003-0213 | DAKLINZA | daclatasvir |
0003-0215 | DAKLINZA | daclatasvir |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
DAKLINZA 85871477 5171750 Live/Registered |
Bristol-Myers Squibb Company 2013-03-08 |